Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

Fig. 1

Patient survival analysis showing the correlation of prognosis or survivability with the expression of hENT1 in TNBC patients. A Distal recurrence survival curve in TNBC patients with high or low expression of hENT1 from GSE25066 and GSE69031 (p = 0.039). B Kaplan–Meier analysis showing TNBC patients (SLC29A1, 201801_s_at) with higher hENT1 expression exhibited better overall survival (p = 0.093), especially in basal-like subset TNBC patients (p = 0.037)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us